...
【24h】

Traversing the Cancer Biomarker Labyrinth

机译:穿越癌症生物标志物迷宫

获取原文
获取原文并翻译 | 示例
           

摘要

Tailoring healthcare decisions based on biological information represents the promise of personalized medicine.A key hurdle slowing progress toward tailored therapeutics is developing appropriate biomarkers for diagnostics, prognostics, and prediction.Despite much research, only a trickle of biomarkers has made it into clinical practice. Researchers, however, are pursuing novel avenues and making headway by dissecting the subtle architecture of normal versus cancerous cells. New approaches include scrutinizing aberrant glycans, microRNAs shedfrom tumors, and epigenetic modifications, as well as mining and merging the vast stores of multi-omics data.
机译:根据生物学信息量身定制医疗保健决策代表了个性化医学的前景。减缓定制疗法进展的一个关键障碍是开发用于诊断,预后和预测的合适生物标志物尽管进行了很多研究,但只有一小部分生物标志物已将其纳入临床实践。然而,研究人员正在探索新颖的途径,并通过解剖正常细胞与癌细胞的微妙结构来取得进展。新方法包括检查异常的聚糖,从肿瘤中脱落的microRNA和表观遗传修饰,以及挖掘和合并大量的多组学数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号